Blanco, Shulamite A.
HRN: 19-02-19 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/23/2023
CEFUROXIME 500MG (TAB)
06/23/2023
06/30/2023
PO
500mg
BID X 7 Days
2nd Degree RMLE; Leukocytosis; UTI
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes